New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494)
Adjuvant Nivolumab in Esophageal Cancer — A New Standard of Care (Editorial in NEJM; subscription required)
Einen Kommentar schreiben
Sie müssen sich anmelden, um Kommentare hinzuzufügen.